Tissue engineering platforms to replicate the tumor microenvironment of multiple myeloma

Methods in Molecular Biology

Volumn 1513, Issue , 2017, Pages 171-191

  Zhang, Wenting ^a   Lee, Woo Y ^a   Zilberberg, Jenny ^b  

^a Stevens Institute of Technology   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Microenvironment; Microfluidics; Multiple myeloma; Perfusion; Three dimensional

Indexed keywords

CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD38 ANTIGEN; CD56 ANTIGEN; MITOMYCIN; SYNDECAN 1; BAYSILON; BIOMATERIAL; DIMETICONE;

CANCER CELL CULTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; OSTEOBLAST; TISSUE CULTURE; TISSUE ENGINEERING; TISSUE SCAFFOLD; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; CELL LINE; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; LAB ON A CHIP; MOUSE; PATHOLOGY; PERFUSION; PERSONALIZED MEDICINE; PHARMACOLOGY; PHYSIOLOGY; PRIMARY CELL CULTURE; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE MARROW CELLS; CELL LINE; CELL PROLIFERATION; CULTURE MEDIA; DIMETHYLPOLYSILOXANES; EQUIPMENT DESIGN; HUMANS; LAB-ON-A-CHIP DEVICES; MICE; MULTIPLE MYELOMA; OSTEOBLASTS; PERFUSION; PRECISION MEDICINE; PRIMARY CELL CULTURE; TISSUE ENGINEERING; TISSUE SCAFFOLDS; TUMOR MICROENVIRONMENT;

EID: 84994358526     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-6539-7_12     Document Type: Chapter

References (43)

1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J (2014) Clinical development success rates for investigational drugs. Nat Biotechnol 32:40-51
2. Cook D, Brown D, Alexander R et al (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419-431
3. Li A, Walling J, Kotliarov Y et al (2008) Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res 6:21-30
4. Domcke S, Sinha R, Levine DA et al (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126
5. Sandberg R, Ernberg I (2005) Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci U S A 102:2052-2057
6. Aggeler J, Park CS, Bissell MJ (1988) Regulation of milk protein and basement membrane gene expression: the influence of the extracellular matrix. J Dairy Sci 71:2830-2842
7. Bhat R, Bissell MJ (2014) Of plasticity and specificity: dialectics of the micro-and macro-environment and the organ phenotype. Wiley Interdiscip Rev Membr Transp Signal 3:147-163
8. Bissell MJ, Hall HG, Parry G (1982) How does the extracellular matrix direct gene expression? J Theor Biol 99:31-68
9. Zhang W, Gu Y, Sun Q et al (2015) Ex vivo maintenance of primary human multiple myeloma cells through the optimization of the osteoblastic niche. PLoS One 10:e0125995.doi:10.1371/journal.pone.0125995
10. Zhang W, Lee WY, Siegel DS et al (2014) Patient-specific 3D microfluidic tissue model for multiple myeloma. Tissue Eng Part C Methods 20:663-670
11. Sachs N, Clevers H (2014) Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 24:68-73
12. Buske P, Przybilla J, Loeffler M et al (2012) On the biomechanics of stem cell niche formation in the gut—modelling growing organoids. FEBS J 279:3475-3487
13. Gu Y, Zhang W, Qiaoling S et al (2015) Microbead-guided reconstruction of the 3D osteocyte network during microfluidic perfusion culture. J Mater Chem B 3:3625-3633
14. Damiano JS (2002) Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2:37-43
15. Li ZW, Dalton WS (2006) Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 20:333-342
16. Nakagawa Y, Nakayama H, Nagata M et al (2014) Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. Int J Oncol 44:1376-1384
17. Schmidmaier R, Baumann P (2008) ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem 15:978-990
18. Tolias P, Toruner GA (2014) Personalized medicine. Future Med 7:461-464
19. Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32:760-772
20. Benien P, Swami A (2014) 3D tumor models: history, advances and future perspectives. Future Oncol 10:1311-1327
21. Wang C, Tang Z, Zhao Y et al (2014) Three-dimensional in vitro cancer models: a short review. Biofabrication 6:022001
22. Hickman JA, Graeser R, de Hoogt R et al (2014) Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J 9:1115-1128
23. Birmingham E, Kreipke TC, Dolan EB et al (2015) Mechanical stimulation of bone marrow in situ induces bone formation in trabecular explants. Ann Biomed Eng 43:1036-1050
24. Jaasma MJ, Plunkett NA, O'Brien FJ (2008) Design and validation of a dynamic flow perfusion bioreactor for use with compliant tissue engineering scaffolds. J Biotechnol 133:490-496
25. Plunkett N, O'Brien FJ (2011) Bioreactors in tissue engineering. Technol Health Care 19:55-69
26. Ferrarini M, Steimberg N, Ponzoni M et al (2013) Ex-vivo dynamic 3-D culture of human tissues in the RCCS bioreactor allows the study of multiple myeloma biology and response to therapy. PLoS One 8:e71613
27. Kwapiszewska K, Michalczuk A, Rybka M et al (2014) A microfluidic-based platform for tumour spheroid culture, monitoring and drug screening. Lab Chip 14:2096-2104
28. Lee JH, Gu Y, Wang H, Lee WY (2012) Microfluidic 3D bone tissue model for high-throughput evaluation of wound-healing and infection-preventing biomaterials. Biomaterials 33:999-1006
29. Lei KF, Wu MH, Hsu CW, Chen YD (2014) Real-time and non-invasive impedimetric monitoring of cell proliferation and chemosensitiv-ity in a perfusion 3D cell culture microfluidic chip. Biosens Bioelectron 51:16-21
30. Polini A, Prodanov L, Bhise NS et al (2014) Organs-on-a-chip: a new tool for drug discovery. Expert Opin Drug Discovery 9:335-352
31. Ocio EM, Richardson PG, Rajkumar SV et al (2014) New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 28:525-542
32. Lonial S, Anderson KC (2014) Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 28:258-268
33. Neri P, Bahlis NJ (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 12:776-796
34. Neri P, Ren L, Azab AK et al (2011) Integrin beta7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 117:6202-6213
35. Damiano JS, Dalton WS (2000) Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma 38:71-81
36. Abdi J, Chen G, Chang H (2013) Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4:2186-2207
37. Yaccoby S, Epstein J (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94:3576-3582
38. Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92:2908-2913
39. Lawson MA, Paton-Hough JM, Evans HR et al (2015) NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. PLoS One 10:e0119546
40. Reagan MR, Mishima Y, Glavey SV et al (2014) Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood 124:3250-3259
41. Kirshner J, Thulien KJ, Martin LD et al (2008) A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood 112:2935-2945
42. Zhang W, Gu Y, Hao Y et al (2015) Well plate-based perfusion culture device for tissue and tumor microenvironment replication. Lab Chip 15:2854-2863
43. Yang X, Ogbolu KR, Wang H (2008) Multifunctional nanofibrous scaffold for tissue engineering. J Exp Nanosci 3:329-345